Moreover, one-time sacubitril/valsartan elevated the post-prandial glucagon in healthy individuals, while over 8 weeks, the drug increased fasting glucagon in obese hypertensive individuals, without changes in fasting glucose or amino acids [34], suggesting a potential role of ARNI in modulating dyslipidemia and metabolic diseases (Figure 3). This evidence concerns the gene GCG and Other metabolic disease.